Infectious Diseases (all articles) | Page 49 of 298 | Links Medicus Content Curation & Alerts in Medicine

Mother-to-child transmission of SARS-CoV-2 has been controversial. Our living systematic review & meta-analysis has just been published in BMJ. Transmission has been confirmed, although it is rare, & is more likely when the maternal COVID-19 is severe.https://t.co/Z15kFIk6Zp

— Asma Khalil (@ProfAsmaKhalil) March 19, 2022

No flight, no bite: ‘Mosquito grounding’ bed net nearly halves malaria infection in Tanzanian children.

1 Apr, 2022 | 08:41h | UTC

News Release: No flight, no bite: ‘Mosquito grounding’ bed net nearly halves malaria infection in Tanzanian children – London School of Hygiene & Tropical Medicine

Original Study: Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial – The Lancet

Invited Commentary: A new generation of long-lasting insecticidal nets – The Lancet (free registration required)

Commentary on Twitter

Mosquitoes developing resistance to the insecticides used in bed nets became a large problem in the fight against malaria.

This study finds that nets treated with a new insecticide cut malaria rates in children *by almost half* compared to the usual ones.https://t.co/rRoyFzIhWf

— Max Roser (@MaxCRoser) March 28, 2022

WHO Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022–2032.

31 Mar, 2022 | 08:45h | UTC

Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022–2032 – World Health Organization

News Release: WHO releases 10-year strategy for genomic surveillance of pathogens – World Health Organization

Commentary on Twitter (thread – click for more)

🆕 Today @WHO published the Global Genomic Surveillance Strategy for Pathogens with Pandemic and Epidemic Potential (2022–2032)

Ambitious, comprehensive, strategic and necessary.

Short thread ⬇️https://t.co/98NMgMhbL6

— Maria Van Kerkhove (@mvankerkhove) March 30, 2022

RCT: Early treatment with ivermectin does not improve outcomes in patients with Covid-19.

31 Mar, 2022 | 08:41h | UTC

Effect of Early Treatment with Ivermectin among Patients with Covid-19- New England Journal of Medicine

Commentary: Ivermectin does not prevent COVID-19 hospitalization, a new study says – NPR

Commentary on Twitter

Ivermectin: the largest randomized, double-blind trial yet conducted, with early treatment, indicates there is no difference compared with placebo. It doesn't work. Period. https://t.co/wiFygjRgkk
just published @NEJM pic.twitter.com/uZ0mMZnO0E

— Eric Topol (@EricTopol) March 30, 2022

RCT: Early outpatient treatment with convalescent plasma reduces the risk of hospitalization in patients with Covid-19.

31 Mar, 2022 | 08:39h | UTC

Early Outpatient Treatment for Covid-19 with Convalescent Plasma – New England Journal of Medicine

Commentaries:

Study finds convalescent plasma can be effective early COVID-19 therapy – Johns Hopkins University School of Medicine

Early Use of High-Titer Plasma Reduced COVID Hospitalizations— Randomized trial that influenced indication shows benefits in a mostly unvaccinated population – MedPage Today (free registration required)

Commentary on Twitter

https://twitter.com/NEJM/status/1509278140433981444

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study in England.

31 Mar, 2022 | 08:29h | UTC

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England – The Lancet Child & Adolescent Health

Invited Commentary: Importance of understanding the reinfection risk of COVID-19 in children – The Lancet Child & Adolescent Health

Commentary on Twitter

Everything we know about #SARSCoV2 tells us that first infection reduces (but doesn’t eliminate) the risk & SEVERITY of further infections, even with new variants. Here is our paper showing this with delta reinfections in kids (work on omicron reinfections in progress)👇 https://t.co/3gDPBHRu18

— Shamez Ladhani (@ShamezLadhani) March 30, 2022

Case-control study: In children 5 to 11 years of age, the Pfizer vaccine showed an effectiveness of 68% against hospitalization caused by the Omicron variant.

31 Mar, 2022 | 08:37h | UTC

BNT162b2 Protection against the Omicron Variant in Children and Adolescents – New England Journal of Medicine

Commentary: COVID vaccination of children age 5-11 cut omicron hospitalizations by 68% – Children’s Hospital Boston

Commentary on Twitter

BNT162b2 vaccination reduced the risk of omicron-associated hospitalization by two thirds among children 5 to 11 years of age. https://t.co/mQcchQqbtH pic.twitter.com/Qzy8qKg1wC

— NEJM (@NEJM) March 30, 2022

A Narrative Review on the approach to antimicrobial use in ventilated patients with multidrug resistant organisms in respiratory samples—to treat or not to treat?

31 Mar, 2022 | 08:27h | UTC

A Narrative Review on the Approach to Antimicrobial Use in Ventilated Patients with Multidrug Resistant Organisms in Respiratory Samples—To Treat or Not to Treat? That Is the Question – Antibiotics

Commentary on Twitter

https://twitter.com/ABsteward/status/1508917245740818438

Nature Outlook: Hepatitis B.

31 Mar, 2022 | 08:05h | UTC

Homepage: Nature Outlook: Hepatitis B

Hepatitis B

Closing in on a cure for hepatitis B

Developing a cure for chronic hepatitis B requires a fresh approach

How to stop mother-to-child transmission of hepatitis B

Simplify access to hepatitis B care

Destigmatizing hepatitis B

Facing the challenge of eliminating hepatitis B

The global fight against hepatitis B is benefitting some parts of the world more than others

Africa’s struggle with hepatitis B

Why hepatitis B hits Aboriginal Australians especially hard

Hepatitis B and the liver cancer endgame

Research round-up: hepatitis B

Charting a new frontier in chronic hepatitis B research to improve lives worldwide

Addressing the unmet need for a functional cure for chronic hepatitis B

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

30 Mar, 2022 | 10:44h | UTC

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square

Commentaries:

Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical

Cohort Study: Short-term outcomes of corticosteroid monotherapy in multisystem inflammatory syndrome in children.

30 Mar, 2022 | 10:40h | UTC

Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children – JAMA Pediatrics

Commentary on Twitter

In this study, corticosteroid monotherapy successfully treated a subset of patients with mild multisystem inflammatory syndrome in children. https://t.co/fuhHeBSaRp

— JAMA Pediatrics (@JAMAPediatrics) March 28, 2022

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

30 Mar, 2022 | 10:42h | UTC

U.S. approves second Covid-19 booster for people 50 and older – STAT

FDA OKs second COVID booster shot for older Americans – CIDRAP

See Guidance: Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

Complicated and uncomplicated S. aureus bacteremia: an international Delphi survey among infectious diseases experts on definitions and treatment.

30 Mar, 2022 | 10:34h | UTC

Complicated and uncomplicated S. aureus bacteremia: an international Delphi survey among infectious diseases experts on definitions and treatment – Clinical Microbiology and Infection

The RECOVERY Trial – two years on.

30 Mar, 2022 | 10:38h | UTC

The RECOVERY Trial – two years on – University of Oxford

How the UK found the first effective Covid-19 treatment — and saved a million lives (about the RECOVERY trial and the effects of Dexamethasone)

Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19

Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

Commentary on Twitter

https://twitter.com/MartinLandray/status/1508492188560371717

The harms of postoperative antibiotic prophylaxis: a teachable moment.

30 Mar, 2022 | 10:36h | UTC

The Harms of Postoperative Antibiotic Prophylaxis: A Teachable Moment – JAMA Internal Medicine (free for a limited period)

M-A: Parenchymal lung abnormalities following hospitalization for COVID-19 and viral pneumonitis.

30 Mar, 2022 | 10:26h | UTC

Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis – Thorax

Cohort Study: Socio-economic variations determine the clinical presentation, etiology and outcome of infective endocarditis.

30 Mar, 2022 | 09:50h | UTC

Socio-Economic Variations Determine the Clinical Presentation, Aetiology and Outcome of Infective Endocarditis: a Prospective Cohort Study from the ESC-EORP EURO-ENDO (European Infective Endocarditis) Registry – European Heart Journal – Quality of Care and Clinical Outcomes

Commentary on Twitter

Infective #endocarditis – do socio-economic factors impact presentation and prognosis? Unfortunately yes, according to data from EURO-ENDO Registry: https://t.co/JdKM5igihR #CVD #EHJQCCO @cpgale3 @diogoasantosfer pic.twitter.com/pkclJdRsdU

— European Society of Cardiology Journals (@ESC_Journals) March 28, 2022